{"id":6621,"date":"2024-11-11T16:27:24","date_gmt":"2024-11-11T14:27:24","guid":{"rendered":"https:\/\/peptiko.gr\/?p=6621"},"modified":"2026-02-07T19:17:55","modified_gmt":"2026-02-07T17:17:55","slug":"bismuth-quadruple-therapy-in-helicobacter-pylori-management","status":"publish","type":"post","link":"https:\/\/peptiko.gr\/en\/bismuth-quadruple-therapy-in-helicobacter-pylori-management\/","title":{"rendered":"Bismuth quadruple therapy in Helicobacter pylori management"},"content":{"rendered":"

The efficacy of single-capsule bismuth quadruple therapy in Helicobacter pylori<\/em> management<\/h2>\n

Helicobacter pylori<\/em><\/a> is a prevalent Gram-negative bacterium that infects more than half of the global population. H. pylori<\/em> is strongly associated with various gastrointestinal diseases, including gastritis, gastroduodenal ulcers, and gastric cancer, as well as systemic conditions like iron-deficiency anemia<\/a> and vitamin B12 deficiency. The eradication of H. pylori<\/em> has long been regarded as the best course of action for managing these conditions. However, the success of therapeutic approaches has been challenged by increasing antibiotic resistance, prompting the need for more effective regimens.<\/p>\n

Recent studies, including data from the European Registry on Helicobacter pylori Management (Hp-EuReg), have underscored the efficacy and safety of bismuth quadruple therapy (BQT), particularly single-capsule BQT (ScBQT). The registry, comprising data from over 300 centers in 38 European countries, provides valuable insights into the evolving landscape of H. pylori<\/em> treatment.<\/p>\n

Single-Capsule Bismuth Quadruple Therapy: A Breakthrough in Eradication Rates<\/h2>\n

Bismuth-based quadruple therapy involves the combination of a bismuth salt, a proton pump inhibitor (PPI), and two antibiotics. Among its formulations, ScBQT, which encapsulates metronidazole, tetracycline, and bismuth in a single capsule administered alongside a PPI, has shown remarkable success. Studies indicate that ScBQT achieves eradication rates exceeding 90% across various geographical regions, regardless of local antibiotic resistance patterns. This consistent performance makes ScBQT a reliable choice for H. pylori<\/em> eradication.<\/p>\n

In comparison, other BQT schemes, where antibiotics are prescribed separately, demonstrate similar effectiveness only when extended to 14 days. This contrasts with the 10-day regimen of ScBQT, which provides equivalent efficacy while simplifying treatment adherence and reducing patient burden.<\/p>\n

Trends in Bismuth Therapy Usage Across Europe<\/h2>\n

Since its introduction in 2013, ScBQT has significantly influenced the treatment landscape for H. pylori<\/em> in Europe. The use of bismuth-based therapies rose from 8.6% in 2013 to 39% by 2021, driven largely by the availability and efficacy of ScBQT. In southwestern Europe, for example, bismuth quadruple therapies account for 75% of all H. pylori<\/em> treatments, with ScBQT leading as the most commonly prescribed regimen.<\/p>\n

This widespread adoption underscores the role of ScBQT as the preferred treatment choice, especially in regions where it is available. In areas without access to ScBQT, traditional BQT formulations remain a viable option, albeit with longer treatment durations and potential challenges in patient compliance.<\/p>\n

Implications for Clinical Practice and Policy<\/h2>\n

The findings from the Hp-EuReg emphasize the need to expand access to ScBQT across Europe and beyond. Its consistent efficacy, ease of administration, and favorable safety profile make it a strong candidate for first-line therapy in regions with high antibiotic resistance and as a rescue therapy in other settings. The availability of ScBQT has the potential to standardize treatment practices, reduce variability, and improve overall eradication rates.<\/p>\n

The study also highlights the importance of adequate PPI dosing in enhancing the effectiveness of BQT. Standard or high-dose PPIs, such as omeprazole 40 mg twice daily, are recommended to achieve optimal outcomes. This observation suggests a need to update dosing recommendations in technical specifications to align with clinical evidence.<\/p>\n

Safety and Tolerability<\/h2>\n

The safety and tolerability of bismuth quadruple therapy (BQT), particularly single-capsule BQT (ScBQT), have been well-documented, making it a reliable option for Helicobacter pylori<\/em> treatment. Data from the Hp-EuReg demonstrate that adherence to ScBQT is remarkably high, exceeding 95% across patient groups. This high adherence can be attributed to the convenience of the single-capsule format, which simplifies the regimen and reduces the likelihood of missed doses. Furthermore, the adverse event (AE) profile of ScBQT is generally mild, with serious adverse events reported in fewer than 1% of cases. The most commonly observed AEs include taste disturbances, diarrhea, nausea, and abdominal pain, with over 70% of these classified as mild or moderate in intensity. Such a profile supports the overall tolerability of the treatment, even when administered in diverse patient populations.<\/p>\n

Despite a 10% rate of treatment discontinuation due to adverse events, the overall safety of ScBQT remains favorable when compared to other H. pylori<\/em> eradication regimens. The serious AE rate is notably low, and the intensity of symptoms seldom interferes significantly with daily activities. This favorable safety profile not only encourages adherence but also underscores the therapy’s viability for first-line and rescue treatment in H. pylori<\/em> management. These findings affirm ScBQT as a well-tolerated option that balances efficacy with patient comfort, enabling its wider adoption in clinical practice.<\/p>\n

Future Directions in H. pylori<\/em> Treatment<\/h2>\n

Further research is warranted to explore the potential of extending ScBQT to a 14-day regimen and to evaluate the impact of newer acid-suppressing agents like potassium-competitive acid blockers (P-CABs) on treatment outcomes. Additionally, ongoing monitoring of treatment trends and effectiveness is essential to adapt therapeutic strategies to emerging resistance patterns and clinical needs.<\/p>\n

Conclusion<\/h2>\n

Single-capsule bismuth quadruple therapy represents a significant advancement in the management of Helicobacter pylori<\/em> infection. Its consistent efficacy across diverse regions, coupled with high patient adherence and a strong safety profile, positions ScBQT as a cornerstone of contemporary H. pylori<\/em> treatment. Expanding its availability and integrating it into standard clinical practice may enhance treatment success rates and streamline management protocols.<\/p>\n

For personalized consultation and tailored treatment strategies, patients are encouraged to contact Dr. Christos Zavos, a board-certified gastroenterologist in Thessaloniki, Greece, through the contact form at peptiko.gr<\/a>, via email at czavos@ymail.com<\/a>, or by calling (+30)-6976596988 or (+30)-2311283833.<\/p>\n

Reference<\/h2>\n
    \n
  1. Olmedo L, Calvet X, Gen\u00e9 E, et al.; Hp-EuReg investigators*. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori<\/i>\u00a0infection between 2013 and 2021: results from the European registry on\u00a0H. pylori<\/i> management (Hp-EuReg). Gut 2024 Oct 26:gutjnl-2024-332804.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    The efficacy of single-capsule bismuth quadruple therapy in Helicobacter pylori management<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[82],"tags":[],"glossary":[],"class_list":["post-6621","post","type-post","status-publish","format-standard","hentry","category-diseases"],"acf":[],"_links":{"self":[{"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/posts\/6621"}],"collection":[{"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/comments?post=6621"}],"version-history":[{"count":3,"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/posts\/6621\/revisions"}],"predecessor-version":[{"id":8572,"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/posts\/6621\/revisions\/8572"}],"wp:attachment":[{"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/media?parent=6621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/categories?post=6621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/tags?post=6621"},{"taxonomy":"glossary","embeddable":true,"href":"https:\/\/peptiko.gr\/en\/wp-json\/\/wp\/v2\/glossary?post=6621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}